Effects of adjunctive inflammatory modulation on IL-1ß in treatment resistant bipolar depression. Journal Article

Authors: Murata, S; Murphy, M; Hoppensteadt, D; Fareed, J; Welborn, A; Halaris, A
Article Title: Effects of adjunctive inflammatory modulation on IL-1ß in treatment resistant bipolar depression.
Abstract: BACKGROUND: Adjunctive inflammatory modulation improved remission rates in treatment-resistant bipolar depression (TRBDD), but reliable biomarkers must be established to characterize the biosignature of TRBDD and the mechanisms underlying treatment response. In this molecular profiling study, we describe TRBDD and treatment response from the standpoint of interleukin-1 Beta (IL-1ß) and KYN/TRP. METHODS: 47 TRBDD patients with moderately severe HAMD-17 scores were randomized to receive either escitalopram (ESC) (10 mg-40 mg daily dose range) + celecoxib (CBX) (200 mg twice daily), or ESC (10 mg-40 mg daily dose range) + placebo (PBO) (twice daily). Plasma cytokine levels were measured in both treatment arms at baseline and week 8, and in a healthy control (HC) group of subjects (N = 43) once. A linear mixed model (LMM) was applied to evaluate whether clinical outcome is related to CBX and changes to biomarkers throughout treatment. A binary logistic regression model was formulated from this series to predict both the primary outcome of treatment response to CBX, and the secondary outcome of diagnosis of TRBDD using age, BMI, gender, and IL-1ß at baseline. RESULTS: Patients receiving ESC + CBX had 4.278 greater odds of responding (p = 0.021) with NNT = 3, and 15.300 times more likely to remit (p  0.001) with NNT = 2, compared with ESC + PBO patients. Patient BMI (p = 0.003), baseline IL-1ß (p = 0.004), and baseline KYN/TRP (p = 0.001) were most predictive of TRBDD diagnosis. By Week 8, responders showed a downtrend in IL-1ß compared to non-responders in the ESC + CBX treatment arm. However, there was no statistical difference in the IL-1ß or KYN/TRP change after treatment between placebo and ESC + CBX group responders/non-responders (p = 0.239, and p = 0.146, respectively). While baseline IL-1ß was elevated in TRBDD compared to HC (p  0.001), there was no difference in IL-1ß between treatment responders at Week 8 compared to HC (p = 0.067). CONCLUSIONS: Elevated IL-1ß and low KYN/TRP at baseline are components of the TRBDD molecular signature. CBX but not baseline IL-1ß or KYN/TRP predict treatment response. Change in IL-1ß and KYN/TRP did not predict treatment response.
Journal Title: Brain, behavior, and immunity
ISSN: 1090-2139; 0889-1591
Publisher: Elsevier Inc  
Date Published: 2020